Executive Chairman Peter Leys commented, “2018 has been a good year for Materialise. Our annual revenues grew by 30% to 184,721 kEUR, our Adjusted EBITDA grew by 61% to 23,526 kEUR, and our deferred revenue from license and maintenance fees increased 3,883 kEUR to 22,606 kEUR, all at the higher end of the range we forecasted at the beginning of the year. In addition, cash flow from operating activities in 2018 was 28,321 kEUR compared to 9,951 kEUR in 2017, and, as a result of the capital we raised in 2018, our cash and cash equivalents at the end of 2018 totaled 115,506 kEUR compared to 43,175 kEUR at the end of last year. This financial strength positions us well to capture new growth opportunities going forward, even if the macro-economic conditions become less favorable.”
PLYMOUTH, Mich., Nov. 27, 2018 – Materialise, in collaboration with Carestream Health, is developing a work-in-progress zero footprint deployment of their pre-operative planning solution for orthopaedists, leveraging Materialise’s OrthoView software. Thanks to enterprise-wide licensing and an enterprise imaging-integrated zero footprint deployment, Materialise and Carestream will be able to give surgeons the freedom to plan procedures in a standard browser, eliminating the requirement for additional software.
CHICAGO – (Nov. 26, 2018). Materialise NV (Nasdaq: MTLS), a world leading 3D printing solutions provider, is working with partners to remove uncertainty and confusion for hospitals and physicians who are incorporating 3D printing into their diagnostic and surgical planning processes.
Materialise has launched a certification program that allows printer manufacturers that partner with the company to have products tested and validated as being fully compatible with Materialise Mimics inPrint software. inPrint is the first and only software to gain clearance from the FDA to develop 3D printed anatomical models for diagnostic and surgical planning uses. The inPrint software is printer- and material-agnostic, allowing Materialise to develop partnerships and solutions to meet a range of hospital and clinician requirements.
Ludwigshafen/Germany, Leuven/Belgium, College Station/Texas, USA November 14th, 2018. BASF Venture Capital is leading the Series A investment round in Essentium, Inc., an innovative developer of disruptive, industrial additive manufacturing solutions headquartered in College Station, Texas. Materialise is one of the co-investors in the Series A investment round in Essentium, Inc. BASF and Essentium have been working together on advanced fused filament fabrication (FFF) solutions using Essentium’s proprietary FlashFuseTM technology for high mechanical strength in the build direction for extrusion printed parts. The two companies are now extending their strategic partnership to establish a consistent global materials supply chain supportive of Essentium’s new High Speed Extrusion (HSE) additive manufacturing platform. Essentium and BASF welcome Materialise to enter this strategic partnership to develop 3D printing software for the Essentium technology.
Frankfurt, Germany - November 12, 2018. Materialise introduces 3D printing innovations that increase productivity and efficiency in the 3D printing process. While technological improvements and material advances are driving the development of new applications, industrial print factories are looking for ways to raise output while reducing costs. Meanwhile 3D printing service bureaus are operating in an increasingly cost-competitive environment. At Formnext, Materialise presents software innovations that will help companies to scale their operations, use resources more efficiently, and reduce costs.